No revenue or guidance to trade on — the stock will move on H2 2026 clinical data readouts across all three programs. Monitor for BBO-8520 pembrolizumab combo data and BBO-11818 expansion cohort results as binary catalysts. Cash runway into 2028 removes near-term financing risk.
Price Chart
Executive Summary
BBOT reported Q1 2026 net loss of $42.1M vs $22.1M a year ago, with R&D spend nearly doubling to $39.8M as three clinical programs advance. The company highlighted encouraging early efficacy data across its RAS-pathway pipeline and reiterated cash runway into 2028, but the widening loss and lack of near-term revenue catalysts keep the stock in a binary-risk clinical-stage profile.
Key Financial Metrics
Key Facts
- Net loss widened to $42.1M in Q1 2026 from $22.1M in Q1 2025
- R&D expenses nearly doubled to $39.8M from $20.6M YoY
- Cash and marketable securities of $388.9M as of March 31, 2026
- Cash runway expected to fund operations into 2028
- BBO-8520 showed 65% ORR and 68% 6-month PFS in KRAS G12C NSCLC monotherapy
- BBO-11818 demonstrated a partial response in pancreatic cancer with 56% tumor reduction
- Updated clinical data across all three programs expected in H2 2026
- EPS of -$526.11 reflects very low share count (80,032 weighted-average shares) post de-SPAC
Financial Impact
Net loss of $42.1M in Q1 2026, up 91% YoY; cash burn rate of ~$36.6M per quarter based on cash decline from $425.5M to $388.9M
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- Widening net loss and increasing R&D spend without near-term commercialization
- Binary risk from H2 2026 clinical data readouts across all three programs
- Low share count (80K) post de-SPAC creates extreme per-share volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293527 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | $2.63 (+46.87%) |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | $2.63 (−61.07%) |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | $2.63 (+70.91%) |
Aug 11, 2026 10w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | $2.63 (−72.08%) |
Jun 22, 2026 18w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | $2.63 (−64.93%) |
May 12, 2026 23w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | $2.63 (−67.45%) |
Apr 21, 2026 26w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | $2.63 (−70.35%) |
Apr 20, 2026 27w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | $2.63 (−72.20%) |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.63 (−74.76%) |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.63 (−74.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers